Press Releases

Nov 05, 2019
Bicycle Therapeutics to Present New Preclinical Data on BT7480, a Novel, Fully Synthetic Bicycle® Tumor-targeted Immune Cell Agonist, at the Society for Immunotherapy of Cancer’s 2019 Annual Meeting
- BT7480 has been selected as the Company’s lead immuno-oncology candidate to advance into IND-enabling studies CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Nov. 5, 2019-- Bicycle Therapeutics plc (NASDAQ: BCYC) a clinical-stage biotechnology company pioneering a new and differentiated class of
Displaying 1 - 10 of 26